On 25 July 2006, orphan designation (EU/3/06/384) was granted by the European Commission to Pharmexa A/S, Denmark, for human telomerase reverse transcriptase peptide (611-626) for the treatment of pancreatic cancer.
The sponsorship was transferred to Gemvax A/S, Norway, in May 2009.
The sponsor’s address was updated in April 2020.
The sponsorship was transferred to Klifo A/S, Denmark, in May 2020.
Human telomerase reverse transcriptase peptide (611-626)
|Disease / condition||
Treatment of pancreatic cancer
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.